Market Overview

Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines


Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing botulinum toxin products for use in aesthetic and therapeutic
indications, today announced the completion of patient enrollment in two
pivotal trials of the company's SAKURA Phase 3 program for its
investigational drug candidate DaxibotulinumtoxinA for Injection (RT002)
for the treatment of moderate to severe glabellar lines in adults.
Glabellar line treatment is the most popular aesthetic procedure for
botulinum toxin and is estimated to have represented nearly $1 billion
of the global market in 2015. Revance's Phase 3 program is comprised of
two pivotal trials evaluating the efficacy, safety and duration of
RT002, as well as a long-term safety trial, the latter of which
continues to enroll patients. The company expects to report topline
results from both pivotal Phase 3 trials in the fourth quarter of 2017.

"Our SAKURA program is designed to confirm RT002's potential to deliver
high response rates and long lasting treatment of frown lines," said Dan
Browne, co-founder, President, and Chief Executive Officer at Revance.
"We believe RT002 will help reduce the number of annual treatments that
could potentially lead to greater patient satisfaction. Data presented
last year from our BELMONT Phase 2 study demonstrated a six-month median
duration of effect. This compares favorably to duration of three to four
months for the treatment of glabellar lines noted in the labels of
commercially available neurotoxins. This pivotal Phase 3 program is
expected to build on the BELMONT results and establish RT002 as the
first long-lasting neuromodulator."

SAKURA Phase 3 Clinical Program

The company's Phase 3 clinical program includes two randomized,
double-blind, placebo-controlled pivotal trials to evaluate the safety
and efficacy of a single administration of RT002 for the treatment of
moderate to severe glabellar lines in adults. The pivotal trials have
enrolled a total of approximately 600 subjects at multiple sites in the
United States and Canada. In both trials, subjects have been randomized
in a 2:1 ratio to either the RT002 or placebo treatment groups,
respectively. Post-treatment, subjects will be followed for at least 24
weeks and up to 36 weeks.

The primary efficacy endpoint of the pivotal trials will be a composite
of the proportion of subjects who achieve a score of 0 or 1 (none or
mild) and a two-point improvement from baseline in glabellar line
severity on the Investigator Global Assessment-Facial Wrinkle Severity
(IGA-FWS) and Patient Facial Wrinkle Severity (PFWS) scales, at maximum
contraction (frown), at Week 4. Duration of the reduction of severity of
the glabellar lines will be assessed as a secondary efficacy endpoint in
the Phase 3 pivotal trials.

In addition to the two pivotal trials, the Phase 3 program includes a
long-term, open-label safety trial, which is designed to evaluate the
long-term safety of RT002 for the treatment of moderate to severe
glabellar lines in adults following both single and repeat treatment
administration. The long-term safety trial is expected to enroll
approximately 1,500 subjects at multiple sites in the US and Canada.
Depending on the number of treatments and duration of follow-up, a
subject may be on trial for a maximum of 84 weeks.

Additional information about the SAKURA Phase 3 program, including
subject eligibility criteria, is available at

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to
the advancement of remarkable science. The company is developing a
portfolio of products for aesthetic medicine and underserved therapeutic
specialties, including dermatology, orthopedics and neurology. Revance's
science is based upon a proprietary peptide technology, which when
combined with active drug molecules, may help address current unmet
needs. Revance's initial focus is on developing daxibotulinumtoxinA, the
company's highly purified botulinum toxin, for a broad spectrum of
aesthetic and therapeutic indications, including facial wrinkles and
muscle movement disorders.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis with the potential to be
the first long-acting neuromodulator. The company holds worldwide rights
for all indications of RT002 injectable and RT001 topical and the
pharmaceutical uses of its proprietary peptide technology platform. More
information on Revance may be found at

"Revance Therapeutics" and the Revance logo are registered trademarks
of Revance Therapeutics, Inc.

Forward Looking Statements

This press release contains forward-looking statements, including
statements related to the process and timing of, and ability to
complete, current and anticipated future clinical development of our
investigational drug product candidates, including but not limited to
initiation and design of clinical studies for current and future
indications, related results and reporting of such results; statements
about our business strategy, timeline and other goals and market for our
anticipated products, plans and prospects; and statements about our
ability to obtain regulatory approval; and potential benefits of our
drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risks that interim results are not indicative of final
results and that clinical trials may not have an effective design or
generate positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our ability to obtain funding
for our operations; our plans to research, develop, and commercialize
our drug product candidates; our ability to achieve market acceptance of
our drug product candidates; unanticipated costs or delays in research,
development, and commercialization efforts; the applicability of
clinical study results to actual outcomes; the size and growth potential
of the markets for our drug product candidates; our ability to
successfully commercialize our drug product candidates and the timing of
commercialization activities; the rate and degree of market acceptance
of our drug product candidates; our ability to develop sales and
marketing capabilities; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for financing;
our ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks. Detailed
information regarding factors that may cause actual results to differ
materially from the results expressed or implied by statements in this
press release may be found in Revance's periodic filings with the
Securities and Exchange Commission (the "SEC"), including factors
described in the section entitled "Risk Factors" of our annual report on
Form 10-K filed February 28, 2017. These forward-looking statements
speak only as of the date hereof. Revance disclaims any obligation to
update these forward-looking statements.

View Comments and Join the Discussion!